Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Leukemia

• Publication date

  1996-04-01

• Fields of study

  Medicine

• Identifiers
  PMID 8618451
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study

  2004cited by this paper
• Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin

  2004cited by this paper
• Selected pharmacologic characteristics of idarubicin and idarubicinol.

  1992cited by this paper
• Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.

  1987cited by this paper
• Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.

  1987cited by this paper
• Low dose oral administration of 4-demethoxy-daunorubicin (idarubicin) in advanced cancer patients

  1986cited by this paper
• Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4‐demethoxydaunomycin

  1986cited by this paper
• Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia.

  1985cited by this paper
• Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.

  1983cited by this paper
• [Model building in pharmacokinetics/Part III: Simplified rules for the deduction of analytical solutions for linear compartment models (author's transl)].

  1977cited by this paper
• Antitumor activity of 4-demethoxydaunorubicin administered orally.

  1977cited by this paper

• Estimating area under the curve from graph-derived summary data: a systematic comparison of standard and Monte Carlo approaches

  2025cites this paper
• Between group comparison of AUC in clinical trials with censored follow-up: Application to HIV therapeutic vaccines

  2023cites this paper
• Between-group comparison of area under the curve in clinical trials with censored follow-up: Application to HIV therapeutic vaccines

  2021cites this paper
• Sensitive Analysis of Idarubicin in Human Urine and Plasma by Liquid Chromatography with Fluorescence Detection: An Application in Drug Monitoring

  2020cites this paper
• Antimalarial Properties of Aqueous Crude Extracts of Gynostemma pentaphyllum and Moringa oleifera Leaves in Combination with Artesunate in Plasmodium berghei-Infected Mice

  2016cites this paper
• Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapy.

  2010cites this paper
• Population pharmacokinetics meta-analysis of plitidepsin (Aplidin®) in cancer subjects

  2009cites this paper
• High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study

  2007cites this paper
• Increased myelotoxicity of idarubicin: Is there a pharmacological basis?

  2007cites this paper
• Modulation of Oral Drug Bioavailability: From Preclinical Mechanism to Therapeutic Application

  2005cites this paper
• Pharmacokinetic Comparison of 120-Hour Infusion Versus Hyperfractionated Oral Administration of Idarubicin

  2004cites this paper
• Increased myelotoxicity of idarubicin: is there a pharmacological basis?

  2003cites this paper
• Effect of drugs on the cardiac transport, metabolism and action of Idarubicin: pharmacokinetic and pharmacodynamic modeling

  2002cites this paper
• Pharmacokinetics and toxicity of idarubicin in the rat

  2001cites this paper
• Pharmacokinetically Guided Administration of Chemotherapeutic Agents

  2000cites this paper
• The Oral Route for the Administration of Cytotoxic Drugs: Strategies to Increase the Efficiency and Consistency of Drug Delivery

  2000cites this paper
• Oral Idarubicin in Patients with Late Chronic Phase Chronic Myelogenous Leukemia or Chronic Myelomonocytic Leukemia

  2000cites this paper
• Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.

  2000cites this paper
• Surveillance thérapeutique des traitements anticancéreux

  2000cites this paper
• An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma.

  1999cites this paper
• Clinical pharmacology of anticancer agents in relation to formulations and administration routes.

  1999cites this paper
• 4. Study Group of Pharmacology in Oncology and Hematology (APOH)

  1998cites this paper
• Model-independent estimation of lag times with first-order absorption and disposition.

  1998cites this paper
• Clinical applications of anticancer drugs targeted to topoisomerase II.

  1998cites this paper
• Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma.

  1997cites this paper